Does Gut Health Effect Fibromyalgia

Does Gut Health Affect Fibromyalgia?

Fibromyalgia remains one of medicine’s most mystifying syndromes—characterised by chronic, widespread pain, fatigue, sleep disturbances, and cognitive difficulties—without a clear aetiology. In this blog, you will explore the emerging evidence linking gut health to fibromyalgia, weaving together findings on small intestinal bacterial overgrowth (SIBO), intestinal permeability (“leaky gut”), dysbiosis, and gut infections. By the end you will have a clear answer to the question that brought you here….does gut health effect fibromyalgia?

The Gut-Musculoskeletal Axis: A Foundation

Fibromyalgia often co-exists with irritable bowel syndrome (IBS), a connection that first caught attention in epidemiologic studies and now points toward shared underlying mechanisms. A systematic review noted that among fibromyalgia patients, IBS is common, and that the gut microbiome—the ecosystem of microorganisms in the digestive tract—may play a pivotal role in symptom severity and quality of life.

Dysbiosis—an imbalance in gut microbial communities—has been increasingly observed in fibromyalgia. The concept posits that disrupted gut ecology can alter intestinal permeability, immune activation, and metabolite profiles, in turn amplifying pain via the gut-brain axis and central sensitisation pathways. (Source)

“The gut microbiome has recently emerged as a potential key mediator of central nociception through various mechanisms, representing a direct link between gut microbial composition and central sensitization, the defining characteristic of fibromyalgia.” (source)

Discover the reasons for your gut symptoms.

View our gut health tests

Dysbiosis in Fibromyalgia

Multiple studies document altered gut microbiome in fibromyalgia. For instance, reductions in Bifidobacterium and Eubacterium—genera involved in neurotransmitter metabolism—have been confirmed, alongside shifts in metabolite levels such as lactic, succinic, and hippuric acid (Source). These metabolomic signatures are not mere curiosities: in one study, levels of succinic acid, taurine, and creatine accurately distinguished fibromyalgia patients from healthy controls with an impressive predictive accuracy (ROC ~90%). (Source)

In other words, certain gut bacteria may shape how pain, fatigue, mood, and other fibromyalgia symptoms are experienced. They do this by releasing metabolites—such as short-chain fatty acids (SCFAs), bile acids, neurotransmitters, and bacterial antigens—that can pass into the bloodstream and influence the body beyond the gut. This exchange forms the foundation of what we call the gut–brain axis: a two-way communication system where the gut microbiome, the immune system, and the autonomic nervous system constantly interact. Together, these regulatory networks can drive changes across multiple body systems, helping explain why disturbances in gut health may ripple outward into widespread effects seen in fibromyalgia. (source)

Leaky Gut and Bacterial Translocation

The integrity of the intestinal barrier may be compromised in fibromyalgia, facilitating the passage of bacterial products into systemic circulation. A pilot cohort study compared 22 fibromyalgia patients to healthy controls and found elevated biomarkers of intestinal permeability—including zonulin-1 (ZO-1), lipopolysaccharide (LPS), anti-β-lactoglobulin IgG, and soluble CD14 (sCD14)—all significantly higher in fibromyalgia. These correlated with self-reported symptoms, supporting the hypothesis that “leaky gut” contributes to systemic inflammation and symptom burden. (Source)

Leaky gut is tested within our Ultimate Gut Health Test.

SIBO (Small Intestinal Bacterial Overgrowth)

SIBO appears strikingly prevalent in fibromyalgia cohorts. Early investigations reported up to 78% of fibromyalgia patients testing positive for SIBO via lactulose breath testing, compared to much lower expected population rates. In one study, antibiotic treatment leading to SIBO eradication resulted in notable improvement—not only in gastrointestinal symptoms like bloating, gas, diarrhoea, and constipation, but also in joint pain.

A landmark double-blind study (source) investigated whether small intestinal bacterial overgrowth (SIBO) might be more prevalent in fibromyalgia than in irritable bowel syndrome (IBS) or healthy controls. Participants completed symptom questionnaires and underwent a lactulose hydrogen breath test, a standard method for detecting SIBO.

The findings were striking: while only 20% of healthy controls showed an abnormal breath test, this rose to 84% in IBS patients and an astonishing 100% in fibromyalgia patients. Not only was SIBO more frequent in fibromyalgia, but the degree of hydrogen production was significantly higher than in IBS (with greater peak hydrogen levels and overall hydrogen exposure). Importantly, the amount of hydrogen produced on the breath test correlated with the severity of somatic pain reported by fibromyalgia patients.

In other words, this study provided the first strong evidence that bacterial overgrowth in the small intestine is not only far more common in fibromyalgia but may also be linked directly to the intensity of pain symptoms.

You can order a SIBO test here.

Gut Infections: Helicobacter pylori and Beyond

Infection with Helicobacter pylori has been examined in fibromyalgia with mixed conclusions. While H. pylori seropositivity ranged widely—from 30% to 68% in fibromyalgia groups versus 17% to 44% in controls—the results were inconsistent, and not always statistically significant across studies. In one Egyptian cohort, higher seropositivity correlated with increased symptom burden across pain, stiffness, mood disturbance, and sleep—yet causality remains unproven. Overall, these data suggest possible association, but fall short of establishing H. pylori as a driver of fibromyalgia.

H. Pylori is also tested for within our Ultimate Gut Health Test.

Therapeutic Interventions: Diet, Probiotics, FMT, RCT Evidence

As an expert guiding readers forward, you must assess therapeutic data critically—especially RCTs, which offer the highest level of evidence.

Probiotics and Gut-Microbiota Therapies

A 2024 systematic review and meta-analysis of 80 RCTs evaluated gut microbiota-based therapies (mainly probiotics involving Bifidobacteria and Lactobacilli) across various autoimmune and rheumatic conditions—including fibromyalgia syndrome. The findings were nuanced: while these therapies appeared to relieve pain in fibromyalgia, they did not significantly improve scores on the Fibromyalgia Impact Questionnaire (FIQ). In specific RCTs, improvement in anxiety symptoms (measured by BDI and BAI) was observed, yet no significant changes were noted in visual analogue pain scales (VAS) or FIQ scores.

These results temper expectations: probiotics may modulate mood or emotional symptoms through the gut-brain axis, but they don’t yet show robust evidence for reducing overall fibromyalgia impact.

Diet: Low-FODMAP and Anti-Inflammatory Diets

Dietary modulation offers a non-pharmacologic avenue to influence gut health. One randomised controlled protocol for a combined anti-inflammatory and low-FODMAP dietary intervention (ClinicalTrials.gov: NCT04007705) was designed to assess effects on pain, fatigue, sleep, GI symptoms, and biomarkers. Existing preliminary data suggest that a low-FODMAP diet can improve pain, fatigue, gastrointestinal symptoms, and quality of life in fibromyalgia, though trials are scant and often of limited quality. (Source) The low-FODMAP approach likely decreases fermentable substrates, reducing gas production and possibly shifting microbial composition—though such changes can also diminish beneficial bacteria like Bifidobacteria. (Source)

Fecal Microbiota Transplantation (FMT)

Emerging data suggest that FMT may offer promise in fibromyalgia. A 2024 open-label, randomised—but non-placebo-controlled—study found improvements in pain, fatigue, and quality of life post-FMT. A broader 2024 review also noted potential benefits, though evidence remains preliminary and insufficient to recommend routine use. FMT may exert effects by restoring microbial diversity and suppressing dysbiosis, yet high-quality, placebo-controlled RCTs are still needed.

Synthesis and Expert Perspective

As an expert, you can weave these threads into a coherent narrative:

1. Biological plausibility is strong. Dysbiosis, increased intestinal permeability, SIBO, and gut-derived inflammatory signalling collectively construct a credible model in which gut health modulates central sensitisation and symptom burden in fibromyalgia.

2. Associative evidence is growing but causality is not yet confirmed. Observational data—including metabolomics, breath testing, and biomarker profiling—reveal striking associations, but controlled interventional data remain limited.

3. RCTs of gut-microbiome interventions offer mixed results. Probiotics may help mood and anxiety but do not consistently reduce core fibromyalgia impact. Dietary interventions show promise on pain and GI symptoms, but studies are few and often not of high methodological quality. FMT is intriguing but unproven.

4. Future research must prioritise rigorous RCTs. We need well-powered, placebo-controlled trials investigating SIBO eradication, targeted diets, probiotics, and FMT—measuring not just pain but also functional outcomes, inflammatory markers, and microbiome changes.

Conclusion

In summary, the evidence increasingly supports the hypothesis that gut health—and specifically dysbiosis, leaky gut, SIBO, and microbial infections—plays a meaningful role in fibromyalgia’s pathogenesis and symptom expression. While randomized controlled data are still emerging, therapeutic strategies targeting the gut offer promising avenues. Clinicians and researchers would benefit from making gut health assessment and modulation part of a comprehensive, multimodal fibromyalgia treatment framework.

References

1. Determining the association between fibromyalgia, the gut… systematic review of microbiome biomarkers in fibromyalgia PMC

2. Dysbiosis, gut-brain axis, microbial metabolite mechanisms in fibromyalgia PMC+1

3. FM and IBS comorbidity, microbiota similarities, FMT potential (review) PMCMDPI

4. Dysbiosis and bacterial metabolite imbalance in FM Wiley Online Library

5. Leaky gut biomarkers in FM (ZO-1, LPS, sCD14) PMC

6. SIBO prevalence (~78%) in fibromyalgia and symptom improvement post-antibiotics ResearchGategutnliver.org

7. Probiotics RCT meta-analysis across autoimmune diseases including fibromyalgia BioMed Central

8. Dietary low-FODMAP/anti-inflammatory RCT protocol/improvements in FM